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Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy
with limited treatment options. Although activating mutations of
the KRAS GTPase are the predominant dependency present in >90%
of PDAC patients, targeting KRAS mutants directly has been chal-
lenging in PDAC. Similarly, strategies targeting known KRAS down-
stream effectors have had limited clinical success due to feedback
mechanisms, alternate pathways, and dose-limiting toxicities in nor-
mal tissues. Therefore, identifying additional functionally relevant
KRAS interactions in PDAC may allow for a better understanding of
feedback mechanisms and unveil potential therapeutic targets.
Here, we used proximity labeling to identify protein interactors of
active KRAS in PDAC cells. We expressed fusions of wild-type (WT)
(BirA-KRAS4B), mutant (BirA-KRAS4BG12D), and nontransforming
cytosolic double mutant (BirA-KRAS4BG12D/C185S) KRAS with the
BirA biotin ligase in murine PDAC cells. Mass spectrometry analysis
revealed that RSK1 selectively interacts with membrane-bound
KRASG12D, and we demonstrate that this interaction requires NF1
and SPRED2. We find that membrane RSK1 mediates negative
feedback on WT RAS signaling and impedes the proliferation of
pancreatic cancer cells upon the ablation of mutant KRAS. Our
findings link NF1 to the membrane-localized functions of RSK1
and highlight a role for WT RAS signaling in promoting adaptive
resistance to mutant KRAS-specific inhibitors in PDAC.
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Atotal of 60,430 new cases of pancreatic cancer were estimatedfor 2021, and the 5-y relative survival rate has consistently
remained below 11% (1). About 85% of these pancreatic cancer
tumors are pancreatic ductal adenocarcinoma (PDAC) (2). Poor
outcomes of PDAC cases result from late diagnoses leading to
unresectable and heterogeneous tumors as well as ineffective
therapies, which only prolong survival on the order of months
(3–5). Mutations in the KRAS proto-oncogene are present in over
90% of PDAC cases and are associated with a poor prognosis (6).
Furthermore, mice expressing mutant KRAS in the pancreas de-
velop precursor lesions, which sporadically progress into frank
PDAC. This progression is accelerated when combined with other
mutations or deletion of tumor suppressor genes (7–11). Addi-
tionally, independent studies have shown that the maintenance of
murine PDAC cells require KRAS (12–14).
As a RAS GTPase, KRAS acts as a molecular switch at the
plasma membrane that relays growth factor signaling from receptor
tyrosine kinases to downstream pathways such as RAF/MEK and
PI3K/AKT (15). GTP binding alters the conformation of the KRAS
G domain, thereby creating binding sites for downstream effectors
to trigger enzymatic cascades that promote cell transformation
(16–19). Intrinsically, KRAS slowly hydrolyzes GTP into GDP to
halt signaling; however, GTPase activating proteins (GAPs) such
as neurofibromin 1(NF1) catalyze this process (20). In contrast,
guanine nucleotide exchange factors, such as son of sevenless
homolog 1 (SOS1), catalyze the exchange of GTP for bound
GDP. In most PDAC cases, KRAS is mutated at the 12th residue
located in the G domain from glycine to either a valine (G12V), or
more commonly, aspartate (G12D). These mutations sterically
prevent the “arginine finger domain” of GAPs from entering
the GTPase site, thereby blocking extrinsic allosteric GTPase ac-
tivation and stabilizing RAS-GTP (21, 22). Activating mutations in
KRAS constitutively trigger RAF/MEK and PI3K/AKT pathways
leading to increased cell proliferation as well as other proonco-
genic behaviors (15). KRAS signaling not only relies on the G
domain but also the C-terminal hypervariable domain (HVR),
which is required to stabilize KRAS on membranes where sig-
naling is most efficient (23–26). Independent studies suggest that
specific biochemical and cellular consequences of KRAS activa-
tion are attributed to the unique properties of the HVR of the
predominant splice form KRAS4B, namely the polybasic domain
and the lipid anchor (27–30). Localization of RAS proteins to the
plasma membrane requires the prenylation of the CAAX motif
(23). Additionally, for KRAS4B, the hypervariable region contains
a highly polybasic domain consisting of several consecutive lysines,
which can interact with the negative charges on the polar heads of
phospholipids and stabilize protein interactions (31). Structural
and biochemical characterization of the HVR and G domain has
contributed to a better understanding of the signaling outputs of
KRAS and led to KRAS-targeting strategies.
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Various approaches to inhibit KRAS include direct inhibition,
expression interference, mislocalization, and targeting of down-
stream effectors (32). Thus far, direct inhibitors against KRAS
have only successfully targeted the G12C mutant, which comprises
2.9% of KRAS mutant PDAC (21, 33). For other KRAS mutants,
targeting downstream effectors of KRAS in pancreatic cancer
remains an alternative approach. Unfortunately, dual inhibition of
MEK and AKT pathways was ineffective in PDAC patients (34).
Difficulty in targeting KRAS due to adaptive resistance and
feedback regulation motivates a better understanding of KRAS
biology (35). For example, although PDAC typically features a
mutant KRAS, there may be a role for its wild-type (WT) coun-
terpart as well as WT RAS paralogs (HRAS and NRAS), which
are GAP sensitive and subject to signaling feedback. While on-
cogenic KRAS has been shown to activate WT HRAS and NRAS
via allosteric stimulation of SOS1 (36), WT KRAS has been
proposed to be a tumor suppressor in some KRAS mutant cancers
based on the commonly observed mutant-specific allele imbalance
that occurs throughout tumor progression (37). Additionally, the
reintroduction of WT KRAS abolished tumor T cell acute lym-
phoblastic leukemia development and impaired tumor growth in
KRAS mutant lung cancer cells in vivo (37–39). The discovery of
novel KRAS protein interactors involved in downstream signaling
or feedback and compensatory pathways may elucidate why in-
hibition of downstream pathways have had limited clinical im-
pact in PDAC. Here, we perform proximity labeling experiments
by expressing a fusion of BirAR118G biotin ligase and KRAS in PDAC
cells, which, in the presence of high concentrations of biotin,
generates reactive biotinoyl-AMP that labels lysines of nearby
proteins, such as interactors of its fusion partner KRAS (40–42).
The biotinylated interactor proteins can be isolated by streptavidin
pulldown and analyzed by proteomics to identify novel protein
interactors (43–45). Because covalent labeling occurs in living
cells, enzymatic labeling may potentially identify transient inter-
actors and protein complexes.
Two recent studies used proximity-dependent biotin identifica-
tion (BioID) labeling methods to identify KRAS interactors in
293T and colon cancer cells (46, 47). These studies uncovered and
validated the functional relevance of PIP5KA1 and mTORC2 in
PDAC cells. However, BirA-KRAS screens in PDACmodels have
not yet been performed. Since the tumor context may determine
protein expression and relevant interactions, we sought to perform
a BirA-KRAS screen in PDAC cells. We hypothesize that proximity
labeling with BioID presents a means for identifying new mutant
KRAS-specific interactions in PDAC, which may unveil new
insights into therapeutic design for this malignancy.
Results
BioID-KRAS in Pancreatic Ductal Adenocarcinoma Cells. To identify
interactors of mutant KRAS in PDAC and better understand
mutant KRAS biology, we performed BioID screening in mouse
PDAC cells. Notably, our studies focused on using BioID with
KRASG12D, the most common mutation in PDAC. To label pro-
teins proximal to KRAS in PDAC cells, we designed and expressed
various BioID fusion proteins with BirA and KRAS4B, the ubiq-
uitously expressed Kras splice isoform (Fig. 1A) (28). We fused both
mutant (KrasG12D) and WT murine Kras (KrasWT) to the C ter-
minus of myc-tagged BirA to create BirA-KrasG12D (B-G12D) and
BirA-KrasWT (B-WT). Since the polybasic domain and CAAXmotif
at the C-terminal are both required for the membrane localization
of KRAS, we designed a membrane-localized BirA control
(B-CAAX) by fusing the last 20 amino acids of murine KRAS to
BirA (48, 49). As the signaling and biological function of KRAS
depend on its membrane localization (50, 51), we sought to
identify membrane-specific KRASG12D interactors by creating a
double mutant BirA-KRAS fusion protein, which harbors an
additional mutation in the CAAX motif (B-G12D/C185S), as a
nontransforming cytosolic comparator. To make the screen rele-
vant to PDAC, we performed the experiment in three cell lines
(mT42, mT93, and mT95) derived from FRT-LSL-KrasG12V-FRT;
LSL-Trp53R172H; Pdx1-Cre;R26-FlpOERT2 (FPC) mouse PDAC
tumors (SI Appendix, Fig. S1A) (52). The endogenous expression
of KRASG12V in this mouse model and isolated cell lines is distin-
guishable from our exogenously expressed BirA-KRASG12D by mass
spectrometry (MS) and can be excised upon 4-hydroxy-tamoxifen
(4-OHT) treatment. This minimizes competition from the endog-
enous mutant KRAS that may confound the identification of BirA-
KRAS interactors.
We first validated the localization of our panel of B-WT,
B-G12D, B-CAAX, and B-G12D/C185S proteins in mT42 FPC
cells by isolating membrane and cytoplasmic fractions using sequen-
tial fractionation (53). As expected, B-WT, B-G12D, and B-CAAX
proteins localized to the membrane, whereas the CAAX mutant
B-G12D/C185S localized to the cytoplasm (Fig. 1B). We validated
these findings by myc-tag immunofluorescence stains of B-WT,
B-G12D, and B-CAAX proteins, which displayed plasma mem-
brane localization, and B-G12D/C185S protein, which was pre-
dominantly cytosolic in PDAC cells (Fig. 1C). Together, these
experiments demonstrate the appropriate localization of the
various fusion constructs.
To ensure that these BirA fusion proteins were functional, we
performed Western blotting analyses of RAS effector pathways
in 293T and 3T3 cells expressing these constructs. Expectedly,
only B-G12D activated RAS effector pathways, ERK and AKT,
in HEK293T and 3T3 cells, respectively (SI Appendix, Fig. S1 B
and C). Additionally, among the BirA-KRAS fusion proteins,
B-G12D was the most potent stimulator of cell proliferation and
exclusively conferred anchorage-independent growth in 3T3 cells
(SI Appendix, Fig. S1 D and E). To determine the functionality of
the BirA ligase, we infected FPC cells to express the B-WT,
B-G12D, B-CAAX, and B-G12D/C185S fusion constructs and
treated the cells with biotin to determine whether the known RAS
interactor RAF1 would be preferentially biotinylated by any of
these fusion proteins. Indeed, B-G12D preferentially biotinylated
more RAF1 than B-WT and B-CAAX but biotinylated compa-
rable levels of RAF1 as B-G12D/C185S (Fig. 1D). This finding
suggests that the interaction of RAF1 with KRAS depends on the
GTP-bound state of KRAS rather than its localization and does
not necessarily cause RAS pathway activation as has been previ-
ously reported (54). We also assessed the functional properties of
these BirA constructs in FPC cells with and without the excision of
the endogenous mutant KRAS. We found that steady-state acti-
vation of ERK and AKT pathways were not markedly altered in
mT42 cells stably expressing these constructs (SI Appendix, Fig.
S1F), suggesting the establishment of feedback loops. We also
found that the expression levels of BirA-KRAS fusion proteins
were comparable to or less than endogenous KRAS levels.
Nonetheless, B-G12D increased proliferation and restored colony
formation after KrasG12V excision in mT93 FPC cells (SI Appendix,
Fig. S1 G and H). These results provide additional evidence that
the BirA-KRASG12D fusion retains oncogenic properties and that
proximity labeling using these constructs could identify functionally
relevant interactors.
Having characterized the functional aspects of our BirA-KRAS
fusion proteins, we sought to compare our KRAS proximity labeling
approach to the standard immunoprecipitation approach for iden-
tifying protein interactors of KRAS. To this end, we harvested
protein lysate from biotin-treated B-WT– and B-G12D–expressing
FPC cells and simultaneously performed a streptavidin pulldown
and immunoprecipitation followed by Western blot analysis. Given
the same input amount and conditions, both approaches were
able to detect similar amounts of RAF1, whereas streptavidin
pulldown was superior in detecting the p110-α subunit of PI3-Kinase
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Fig. 1. Properties of BirA-KRAS fusions. (A) Design of BirA-KRAS fusion constructs. Myc-tagged BirA was fused to the N terminus of murine WT KRAS4B or
mutant KRAS4BG12D with a short glycine linker (GGSG). Membrane-localized BirA was created by fusing the last 20 amino acids of murine KRAS to myc-tagged
BirA. KRAS4BG12D/C185S was created by mutating the cysteine residue in the CAAX prenylation motif to mislocalize the protein. (B) mT42-2D cells expressing
B-WT, B-G12D, B-CAAX, and B-G12D/C185S were sequentially fractionated into cytosolic and membrane isolations and probed for myc-tag, as well as EGFR and
AKT representing membrane and cytosolic controls, respectively. (C) Immunofluorescence (IF) of B-WT, B-G12D, B-CAAX, and B-G12D/C185S in mT93-2D cells.
Staining of the myc-tagged BirA fusions are represented in red while DAPI-stained nuclei are represented in blue in the IF images. The arrows indicate the
profiles taken for the relative fluorescent intensities from one edge to the other edge in cells (adjacent panels). (D) mT95-2D FPC cells were infected to express
B-WT, B-G12D, B-CAAX, B-G12D/C185S, or empty control. Cells were incubated with 50 μM biotin for 24 h prior to lysis and streptavidin pulldown. Elutions and
1.5% input were probed for RAF1 and myc-tag BirA. (E) Lysate from mT95 expressing B-WT and B-G12D was used for both immunoprecipitation (IP) and
streptavidin (SA) pulldown under similar lysis and washing conditions and probed for RAF1, p110-α, and the myc-tagged BirA-Kras fusions.
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(Fig. 1E). Stoichiometry may limit the immunoprecipitation approach
such that only a fraction of enriched B-G12D molecules coprecipi-
tates p110-α; however, in the proximity labeling approach, a single
molecule of B-G12D may biotinylate several molecules of p110-α,
increasing its detection by streptavidin pulldown. Because BioID was
more sensitive in detecting the interaction of p110-α with KRAS than
immunoprecipitation, we set out to employ this approach to identify
interactors by MS.
Proximity Labeling Identifies RSK1 as a Mutant- andMembrane-Specific
KRAS Interactor. To detect interactors of oncogenic KRAS, we
performed BioID-MS analysis on three biological replicates of
murine FPC tumor cells (mT42, mT93, and mT95). For each
parental cell line, we generated cell lines stably expressing each of
our BioID constructs (B-WT, B-G12D, B-CAAX, and B-G12D/
C185S). The comparison of B-G12D to B-WT and/or B-G12D to
B-G12D/C185S would enable the detection of mutant-specific
and/or membrane-specific interactors, respectively (Fig. 2A). To
determine whether endogenous mutant KRASG12V could affect
the interactors identified, these cells were treated with 4-OHT to
ablate the expression of KrasG12V or dimethyl sulfoxide (DMSO)
as a vehicle control for 3 d prior to biotin treatment, followed by
lysate harvest, streptavidin pulldown, and MS analysis. To account
for differences in BirA expression in each cell line and the vari-
ability in the number of peptides in each run for MS, we nor-
malized the quantitative peptide abundance to the BirA counts for
each experiment.
Several observed peptides validated this approach for both the
vehicle-treated (Fig. 2B) and 4-OHT–treated cells (SI Appendix,
Fig. S2A). MS detected shared KRAS peptides and also identified
the G12-containing peptide across the three full-length BirA-KRAS
variants. Interestingly, G12V peptides were not found in any
of the samples run, suggesting that either the BirA tag prevents
KRASG12D:KRASG12V dimer formation or that such heterodimers
may be too scarce to detect. Additionally, samples with an intact
CAAX box enriched for membrane-localized proteins, such as
FAM129B (also known as niban-like protein 1 or MINERVA),
compared to samples from cytosolic B-G12D/C185S. B-G12D and
B-G12D/C185S had similar biotinylation levels of RAF1, whereas
B-WT and B-CAAX labeled less RAF1, consistent with ourWestern
blot results (Fig. 1D).
To identify KRASG12D effectors, we compared the proteins
enriched by B-G12D and B-WT from our BioID-MS experi-
ments and nominated 91 protein matches that met the criteria of
being enriched in at least two out of three biological replicates in
the setting of the endogenous mutant KrasG12V allele. To further
prioritize this list, we also queried for membrane-specific can-
didates identified by comparing B-G12D to B-G12D/C185S and
found 255 proteins in at least two out of three biological replicates.
Among them, 66 candidate proteins were both mutant specific and
membrane specific (SI Appendix, Table S1 and Fig. S2B). Inter-
estingly, when sorted by membrane enrichment, ARAF was pref-
erentially biotinylated at the membrane whereas RAF1 and BRAF
were both comparably labeled by B-G12D and B-G12D/C185S (SI
Appendix, Table S2 and Fig. S2C). Although the direct interaction
of KRAS and ARAF is well established, these data suggest that
our approach could map spatially distinct proximal interactors
and uncover dynamic KRASG12D interactors on the membrane.
To further refine our list and prevent confounding effects of
endogenous mutant KRAS due to competition for substrates, we also
performed BioID-MS analysis on the same BirA-KRAS–expressing
FPC cells treated with 4-OHT to excise the endogenous mutant
KrasG12V allele (SI Appendix, Fig. S2D). By prioritizing candidates
that were nominated in the mutant-specific and membrane-specific
comparison for both the vehicle and 4-OHT conditions, we further
narrowed our list to 32 proteins (Fig. 2C). Of these proteins, 11
matches were known interactors or KRAS effectors, including
RAF family members (ARAF, BRAF, and RAF1), SPRED1,
SPRED2, NF1, MLLT4, RIN1, and mTORC2 complex members
(MAPKAP1, RICTOR, and DEPTOR) (Fig. 2D and SI Appendix,
Table S3). Of the remaining 21 candidates, PLEKHA2, MYO1E,
and RPS6KA1 (RSK1) were also enriched in the B-G12D to
B-WT comparison as previously reported in BioID screens in
HEK293 cells (47, 55). Several known RAS interactors, including
PI3K, KSR, RALBP, SOS1, and PIP5KA1, were not detected
in our MS data set, suggesting that additional approaches may be
needed to increase the sensitivity of BioID assay in PDAC cells.
Nonetheless, ARAF and RSK1 were the most consistently enriched
candidates in the B-G12D to B-WT comparison in the 4-OHT
setting.
Of the interactors that were nominated to be both KRASG12D
specific and plasma membrane localized, RICTOR, ARAF, and
RSK1 were among those validated by Western blot analysis of
the BioID samples (Fig. 2E). To validate the RSK1–KRAS in-
teraction and determine whether it is stable and therefore amenable
to immunoprecipitation, we performed myc-tag coimmunoprecipi-
tation in parallel with streptavidin pulldown of lysates from FPC
cells expressing either B-WT or B-G12D. Unlike ARAF, RSK1
was only detected by streptavidin pulldown of B-G12D samples
and failed to appreciably enrich by immunoprecipitation (Fig. 2F
and SI Appendix, Fig. S2E), suggesting that the RSK1–KRASG12D
interaction is transient, weak, or indirect.
NF1 Recruits RSK1 to the Oncogenic KRAS Interactome.Unlike RAFs
and the mTORC2 complex, RSK1 lacks a known RAS-binding
domain (RBD). Therefore, we reasoned that the proximity of
RSK1 to oncogenic KRAS may depend upon another protein in
murine PDAC cells, similar to the dependency of RICTOR on
MAPKAP1 for proximity to KRAS (47). To test this hypothesis,
we employed both BioID and CRISPR/Cas9 knockout (KO)
approaches. BioID enables the detection of transient or weak
KRASG12D interactors, which are difficult to identify by immu-
noprecipitation, whereas the selective ablation of proteins in the
KRASG12D biotinylated interactome enables the identification
of proteins that promote the proximity of RSK1 to KRASG12D
on the membrane. Accordingly, we investigated whether ablating
membrane-specific proximal interactors of B-G12D, such as
MAPKAP1, RICTOR, and NF1, would abolish the proximity
biotinylation of RSK1 by B-G12D in mT42 and mT93 cells. As
expected, MAPKAP1 KO decreased the KRASG12D-mediated
biotinylation of RICTOR; however, the depletion of neither
mTORC2 component decreased RSK1 biotinylation (Fig. 3A).
Interestingly, only NF1 depletion abrogated RSK1 biotinylation,
suggesting that NF1 selectively mediates RSK1 interaction with
oncogenic KRAS (SI Appendix, Fig. S3 A and B). Since NF1 loss
promotes WT RAS activation, competition for RSK1 between
WT RAS and mutant KRAS could provide an alternative ex-
planation for the decreased RSK1–KRASG12D interaction upon
NF1 KO. To exclude this possibility, we excised the endogenous
mutant KRAS in FPC cells expressing either B-G12D or B-WT
and then ablated Nf1 with CRISPR/Cas9. We hypothesized that
if WT KRAS could compete for RSK1 binding, then the complete
ablation of oncogenic KRAS in B-WT–expressing cells would lead
to elevated RSK1 biotinylation. On the contrary, we found that
RSK1 was biotinylated in B-G12D but not B-WT–expressing cells
(SI Appendix, Fig. S3B), suggesting that the decrease in RSK1–
KRASG12D interaction upon NF1 loss cannot be explained by WT
KRAS activation. Since RSK1 requires NF1 to interact with
KRASG12D on the membrane, and SPRED proteins are essential
for the membrane recruitment of NF1 to the RAS interactome
(56, 57), we tested whether KO of Spred1 and Spred2 would decrease
the RSK1–KRASG12D interaction, measured by RSK1 biotinylation.
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Fig. 2. Proximity labeling nominates RSK1 as a mutant- and membrane-specific KRAS interactor. (A) Schematic of the method for determining mutant-
specific interaction by comparing B-G12D to B-WT and membrane-specific interactions by comparing B-G12D to B-G12D/C185S. (B) MS relative quantification
of internal control KRAS peptides and positive controls (RAF1 and niban-like 1) after normalization to BirA counts for B-WT, B-G12D, B-CAAX, and B-G12D/
C185S samples from vehicle-treated FPC cells. Error bars represent SEM (n = 3). (C) Venn diagram of the overlap of candidates that met the criteria for being
mutant specific and membrane specific in both the 4-OHT–treated and control-treated conditions for two out of three biological replicates. The 32 candidates
met all criteria. (D) Enrichment of peptide abundances for the 32 candidate interactors as well as KRAS and BirA control peptides. Known KRAS interactors
include RAF members (purple), NF1/SPRED proteins (blue), mTORC2 (magenta), and RBD-containing proteins (orange) with the internal controls BirA and
KRAS (yellow). Enrichment is plotted on a scale of log base 10. (E) BioID was performed on mT42 expressing B-WT, B-G12D, B-CAAX, or B-G12D/C185S
followed by Western blot analysis to confirm RICTOR, RSK1, ARAF, BRAF, and RAF1 as B-G12D substrates. (F) mT42 cells expressing B-WT and B-G12D were
treated with 50 μM biotin for 24 h and harvested in HEPES-based Nonidet P-40 lysis buffer. Lysates were either incubated for 4 h with streptavidin (SA) beads
or 3 h with myc-tag antibody followed by 1 h with protein G Dynabeads to compare the performance of BioID to coimmunoprecipitation. SA pulldowns and
immunoprecipitations (IPs) were analyzed by Western blot for the detection of NF1, p110-α, RSK1, ARAF, RAF1, and myc-tag.
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Although we could not confirm SPRED2 depletion at the protein
level due to the lack of suitable antibodies, we validated successful
gene editing at the target sites of both guide RNAs against Spred2
(SI Appendix, Fig. S3C). Whereas guides directed against Spred1
slightly decreased NF1 biotinylation, Spred2 but not Spred1 deple-
tion abolished RSK1 biotinylation (Fig. 3C and SI Appendix, Fig.
S3D), suggesting that a SPRED2/NF1 membrane complex bridges
the interaction between RSK1 and oncogenic KRAS. In line with a
Fig. 3. NF1 recruits RSK1 to the oncogenic KRAS interactome. (A) BioID of mT42 and mT93 expressing B-G12D with CRISPR depletion of MAPKAP1 and
RICTOR were analyzed by Western blot to detect the biotinylation of these mTORC2 components by B-G12D. (B) BioID of mT42, mT93, and mT95 expressing
B-G12D with CRISPR depletion of NF1. (C) BioID of mT93 expressing B-G12D with CRISPR depletion of NF1, RSK1, SPRED1, and SPRED2. (D) FPC cell lines
expressing B-G12D were treated with 500 nM trametinib during the 24 h biotin incubation. The lysates and streptavidin pulldown were analyzed for the
presence of RSK1, NF1, ARAF, and myc-tag as well as the phosphorylation status of MAPK. (E) The 5-d cell proliferation curves of mT42 cells expressing B-G12D
treated with 5, 50, 200, 500 nM trametinib were compared to negative control DMSO and positive control gemcitabine.
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mutant KRAS interactome comprising RSK1, SPRED2, and NF1,
these proteins were nominated as the top 13th, 14th, and 20th
interactors specific to KRASQ61H in the human cell map dataset
(55). Taken together, our results demonstrate that the proximity
of RSK1 to KRASG12D depends on NF1 and SPRED2 and sug-
gest a function for these negative regulators of RAS signaling.
RSK1 to 4 are a family of serine/threonine kinases known to
be activated by ERK signaling and translocated to the plasma
membrane transiently and in an ERK-dependent manner upon
EGF stimulation (58, 59). To test whether MEK/ERK pathway
activation regulates the interaction between RSK1 and mutant
KRAS, we treated B-G12D–expressing FPC cells with 500 nM of
the MEK inhibitor trametinib or vehicle control during the biotin
incubation of the BioID assay and performed streptavidin pulldown
and Western blot for RSK1. MEK inhibition markedly decreased
phospho-ERK levels and abrogated RSK1 biotinylation by B-G12D
(Fig. 3D), suggesting that the RSK1–KRASG12D interaction de-
pends on MEK/ERK pathway activation. To determine whether
the abrogation of KRASG12D-mediated RSK1 biotinylation is a
secondary effect of suppressing cellular proliferation rather than
a specific effect of inhibiting the MEK/ERK pathway, we eval-
uated the proliferation of mT42 G12D-expressing cells upon
treatment with 20 nM gemcitabine, a cytotoxic drug, or 5, 50, 200,
and 500 nM trametinib. As expected, gemcitabine suppressed the
proliferation of these cells. Similarly, trametinib inhibited their
proliferation in a concentration-dependent manner (Fig. 3E).
Having confirmed the effects of these drugs on cellular prolifer-
ation, we repeated the BioID experiment with increasing doses of
trametinib, vehicle control, or 20 nM gemcitabine. Western blot
analyses confirmed the loss of RSK1 biotinylation upon the inhi-
bition of ERK activation, whereas RSK1 biotinylation was mostly
unchanged in gemcitabine-treated cells (SI Appendix, Fig. S3E),
thereby confirming that the loss of RSK1 biotinylation upon MEK
inhibition is a direct consequence of MEK/ERK pathway inhibi-
tion. Since ERK-mediated phosphorylation of RSK1 has been
previously linked to its membrane translocation (59), we sought to
determine whether a decrease in RSK phosphorylation by ERK




Fig. 4. Membrane-localized RSK1 exerts negative
feedback on WT RAS. (A) FPC cell line mT42 cells
ectopically expressing RSK1, myr-RSK1, or empty
vector control were plated for cell proliferation and
treated with DMSO or 4-OHT, then measured by
CellTiter-Glo luminescence assay every day for 4 d.
(B) mT42 FPC cells ectopically expressing RSK1, myr-
RSK1, or empty vector control were treated with
DMSO or 4-OHT and analyzed by Western blot.
Gemcitabine was used as a proliferation control.
Immunoblotting was performed for RSK1 with RAS
pathways represented by phospho-ERK and phospho-
AKT, and the RSK1 substrates, phospho-EPHA2 and
phospho-S6. (C) MIA PaCa-2 cells expressing RSK1,
myr-tag RSK1, and empty vector control were seeded at
2,000 cells per well and treated with either 100 nM
AMG 510 or DMSO control, then measured by CellTiter-
Glo luminescence assay every day for 4 d. (D) MIA
PaCa-2 cells were seeded at 2,000 cells per well and
treated 24 h after seeding with 5 μM BI-3406 or DMSO
control and AMG 510 (from 5 μM to 0.1 nM). Cell vi-
ability was measured after 4 d with CellTiter-Glo. (E)
mT42 cells were seeded at 1,000 cells per well and
treated with 4-OHT or DMSO control and BI-3406 in a
dose–response manner (from 20 μM to 2 nM). Cell
viability was measured using CellTiter-Glo Lumines-
cence assay at day 4. (F) FPC cell line mT42 cells were
treated with 5 μM BI-3406, 20 nM trametinib, or
DMSO vehicle control in the presence or absence of
mutant KRAS by treatment with DMSO vehicle control
or 4-OHT, respectively. Immunoblotting was performed
for RAS pathways by phospho-ERK and phospho-AKT
and the RSK1 substrate phospho-S6.
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To this end, we treated mT42 cells with 50 nM trametinib and
performed Western blot analysis for phospho-RSK (S380).
Phospho-RSK decreased upon MEK inhibition, supporting a
model in which MEK/ERK pathway inhibition reduces RSK
phosphorylation and regulates its ability to interact with NF1 (SI
Appendix, Fig. S3F). Since ERK activation induces the expression
of negative regulators of the RAS pathway, including SPRED,
SPROUTY, and DUSP family proteins, we asked whether ERK
deactivation via MEK inhibition decreases SPRED1/2 expression,
thereby preventing the membrane localization and recruitment
of the NF1/RSK1 complex to the mutant KRAS interactome.
Indeed, we found that DUSP6, SPRED1, and SPRED2 were all
potently down-regulated following MEK inhibition in mT42
FPC cells in a time- and concentration-dependent manner (SI
Appendix, Fig. S3G), providing an additional explanation for the
loss of RSK1 biotinylation by oncogenic KRAS in the context of
MEK inhibition.
Membrane-Localized RSK1 Exerts Negative Feedback on WT RAS.
Having established an active KRAS interactome including NF1
and RSK1, we sought to determine a functional role for membrane-
localized RSK1 in PDAC cells. RSK1 is a known ERK pathway
effector, and membrane-targeted RSK1, considered to be consti-
tutively active, can confer MEK independence and mediate pro-
survival signals in IL-3–dependent cells (60). However, in other
cellular contexts, membrane-localized RSK1 has also been shown
to inhibit RAS signaling (61). As KRAS localizes to the plasma
membrane, we used a myristoylation (myr) tag to target RSK1 to
the plasma membrane (62) (SI Appendix, Fig. S4A). To identify
whether membrane-targeted RSK1 regulates the RAS pathway or
contributes to RAS-mediated transformation in PDAC cells, we
retrovirally introduced RSK1 or myr-tagged RSK1 into parental
mT42 cells and derivative cell lines stably expressing our tagged
KRAS variants, B-WT, B-G12D, and B-G12D/C185S. For com-
parison, we also included overexpression of ARAF and myr-tagged
ARAF as well as an empty vector control. These cells were plated
sparsely and treated with 4-OHT for 3 d to excise endogenous
KrasG12V before crystal violet staining to measure foci formation.
Expectedly, mT42 cells expressing B-G12D formed colonies nor-
mally despite the removal of endogenous KrasG12V, whereas the
parental cells and cells with overexpression of B-WT and B-G12D/
C185S were unable to rescue this loss and therefore exhibited less
colonies (SI Appendix, Fig. S4 B–D). Myr-tagged ARAF, but not
untagged ARAF, was able to partially rescue the loss of KRASG12V,
consistent with the observation that membrane-targeted ARAF
does not require active KRAS to activate downstream signaling
(63). In contrast, myr-RSK1 further inhibited colony formation of
mT42 parental cells and cells with either B-WT or B-G12D/C185S
following the excision of KrasG12V. Similarly, compared to empty
vector, RSK1, or kinase-dead RSK1 expression, myr-RSK1 ex-
pression in mT42 FPC cells markedly attenuated proliferation
following KrasG12V excision (Fig. 4A, Top) but had no effect on
cellular fitness when endogenous KrasG12V was present (Fig. 4A,
Bottom). We further validated this finding in mT93 cells (SI Ap-
pendix, Fig. S4E) and then sought to dissect the molecular under-
pinnings of this finding. Since membrane-targeted RSK produces
a growth suppression phenotype only in cells lacking oncogenic
KRAS, we hypothesized that this phenotype depends on the in-
hibition of WT RAS signaling.
To determine whether membrane-targeted RSK1 suppresses
cellular proliferation by inhibiting the RAS pathway, we introduced
empty vector, RSK1, kinase-dead RSK1, or myr-RSK1 to mT42
cells and treated the cells with either 4-OHT or DMSO control.
We confirmed that these constructs were correctly expressed and
functional by immunoblotting (Fig. 4B). As expected, cells expressing
RSK1 or myr-RSK1 showed increased activation of RSK1 substrates
such as S6 and EPHA2. There were no notable differences in the
phosphorylation levels of ERK and AKT in the presence of en-
dogenous mutant KRAS. However, upon mutant KRAS abroga-
tion, phospho-ERK levels were markedly reduced in myr-RSK1
compared to kinase-dead RSK1 and empty vector–expressing
cells. Importantly, mT42 empty vector–expressing cells treated
with 20 nM gemcitabine exhibited no attenuation of ERK acti-
vation, indicating that the reduction of RAS signaling induced by
myr-RSK1 is not a consequence of reduced proliferation. We also
performed these experiments in mT93 cells and obtained similar
results (SI Appendix, Fig. S4F). Collectively, these findings suggest
that membrane-targeted RSK1 selectively exerts negative feed-
back on WT RAS signaling.
To extend these findings to human PDAC, RSK1 and myr-RSK1
were ectopically expressed in MIA PaCa-2 cells, which harbor a
KRASG12C mutation that can be targeted by the commercially
available KRASG12C-specific inhibitor AMG 510 (64). To test
whether membrane-localized RSK1 might affect cell prolifera-
tion as a function of the observed changes in RAS signaling
pathways, we cultured RSK1-, myr-RSK1-, or empty vector–
expressing MIA PaCa-2 cells with DMSO or 100 nM AMG 510.
Whereas overexpression of RSK1 and myr-RSK1 had no effect
on the proliferation of mT42 cells treated with DMSO, cells
expressing these constructs, particularly myr-RSK1, exhibited in-
creased sensitivity to 100 nM AMG 510 (Fig. 4C). To further
validate these results using various concentrations of AMG 510,
we performed dose curves in MIA PaCa-2 cells expressing empty
vector, RSK1, and myr-RSK1 and similarly found that the
blockade of oncogenic KRAS with AMG 510 sensitized these cells
to RSK1 and myr-RSK–induced growth suppression (SI Appendix,
Fig. S4G). This effect could not be induced by 20 nM gemcitabine
(SI Appendix, Fig. S4H, Top), suggesting that AMG 510 elicits
RSK1-mediated growth suppression through the blockade of on-
cogenic RAS pathway, rather than through its secondary effects on
cellular fitness. To determine whether the attenuation of effector
pathways downstream of oncogenic KRAS modulates the sensi-
tivity to RSK1 expression, we treated MIA PaCa-2 cells expressing
control and RSK constructs with 20 nM trametinib and performed
proliferation assays. Interestingly, myr-RSK1 but not untagged
RSK1 reduced proliferation following trametinib treatment (SI
Appendix, Fig. S4H, Bottom). As the growth-suppressive effect of
RSK1 occurs exclusively at the membrane, and membrane-
targeted but not untagged RSK1 can bypass cellular control of
its membrane localization, this result suggests that direct MEK
inhibition has a greater effect on preventing RSK1 membrane
localization compared to upstream oncogenic KRAS inhibition.
Next, we sought to confirm whether membrane RSK1 inhibits
RAS effector pathways following oncogenic KRAS blockade in
MIA PaCa-2 cells in a similar manner to our prior findings in
FPC cells. To this end, we treated MIA PaCa-2 cells expressing
control and RSK constructs with 100 nM AMG 510 and harvested
protein lysates for Western blot analyses at 1 h, 1 d, and 3 d after
drug treatment. Remarkably, RSK1 and myr-RSK1 attenuated
ERK activation especially following 1 d of AMG 510 treatment
(SI Appendix, Fig. S4I). These findings nominate RSK1 as an
interactor of mutant KRAS that bridges the downstream acti-
vation of ERK signaling to the upstream negative regulator of
WT RAS, NF1. This suggests that RSK1/NF1 participates as a
dual negative feedback inhibitor of WT RAS, consistent with
previously described RSK1-mediated negative feedback that
involves NF1 (65) and SOS1 (61). The resistance of PDAC cells
to membrane-targeted RSK1 may reflect the indifference of
oncogenic KRAS to NF1 GAP activity and less dependence on
SOS1-mediated GTP loading compared to WT RAS.
Given the specificity of membrane RSK1 to WT RAS and
because RSK1 has been previously shown to feedback inhibit
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RAS/ERK signaling through the inhibition of SOS1 or through
its activation of NF1 (61), we asked whether WT RAS inhibi-
tion through selective pharmacological inhibition of SOS1
could phenocopy the effects of membrane-targeted RSK. Ac-
cordingly, we treated MIA PaCa-2 cells with a combination
AMG 510, to abrogate oncogenic KRAS signaling, and a se-
lective SOS1 inhibitor, BI-3406, to block WT RAS signaling.
Although MIA PaCa-2 cells have undergone loss of heterozy-
gosity and do not possess WT KRAS, this cell line expresses
other RAS isoforms, HRAS and NRAS (SI Appendix, Fig. S4J),
which are amenable to mutant KRAS-induced negative feed-
back inhibition and have been recently shown to exhibit in-
creased activation following KRASG12C inhibition (66, 67).
Indeed, we found that BI-3406, a selective SOS1 inhibitor, en-
hanced the AMG 510-induced growth suppression in MIA PaCa-
2 cells (Fig. 4D and SI Appendix, Fig. S5A). We also obtained
similar results using NCI-H358, a KRASG12C non–small cell lung
cancer model (SI Appendix, Fig. S5B, Left). Expectedly, SUIT2
PDAC cells with KRASG12D were completely resistant to the drug
combination (SI Appendix, Fig. S5B, Right). SOS1 inhibition may
impair GDP-to-GTP KRASG12C cycling, thereby increasing the
efficacy of AMG 510 through increased availability of its substrate
rather than direct inhibition of WT RAS (68). To validate the
effect of SOS1 inhibition on WT RAS specifically, we employed
our FPC model, which precludes the contribution of mutant
KRAS GTP loading through genetic deletion of KRASG12V.
KrasG12V deletion combined with SOS1 inhibition abrogated the
proliferation of FPC cells (Fig. 4E and SI Appendix, Fig. S5C),
thereby supporting the notion that the blockade or loss of onco-
genic KRAS eliminates negative feedback signaling on WT RAS.
Notably, excision of mutant RAS modestly enhanced the effect of
trametinib in these cells (SI Appendix, Fig. S5D). The efficacy of
SOS1 inhibition upon the loss of endogenous mutant KRAS im-
plicates WT RAS in mediating the adaptive response to oncogenic
KRAS-directed therapies and suggests combination strategies
involving dual targeting of oncogenic KRAS and WT RAS in
KRAS-driven cancers. Finally, we sought to determine whether,
similarly to membrane-targeted RSK, pharmacological blockade
of WT RAS signaling would attenuate downstream RAS effector
pathways upon ablation of oncogenic KRAS. Indeed, treatment
with 5 μM BI-3406 following the excision of endogenous mutant
KRAS abolished both ERK and AKT activation, consistent with
the inhibition of WT RAS signaling (Fig. 4F). Our findings
collectively provide support for a model in which oncogenic
KRAS elicits negative feedback on WT RAS through NF1/RSK1
(Fig. 5A). The loss of this feedback signaling through oncogenic
KRAS deletion or blockade disinhibits WT RAS and provides a
mechanism for adaptive resistance to oncogenic KRAS-directed
therapies (Fig. 5B).
Discussion
While prior BirA-RAS studies have included other RAS isoforms
and cell types, our experiments focused on PDAC to identify
relevant mutant KRAS interactors in this malignancy (46, 47). In
addition, the normalization of peptide counts to the detection of
BirA increased the robustness of the analyses as suggested by the
detection of internal and positive controls. It is notable that some
biotinylated proteins, such as p110-α, could not be verified by MS,
suggesting that the sensitivity of MS may be below the threshold
for certain proteins and therefore additional fractionation meth-
ods should be considered for future BioID-MS work. Nonetheless,
our approach identified 32 candidate interactors of KRASG12D, 11
of which have been previously reported. Our work showed that
ARAF differs from the other RAF family kinases, BRAF and
RAF1, by being predominantly membrane-localized with mutant
RAS. Since membrane-bound ARAF is transforming even in the
absence of active KRAS, this prompts further investigation of
potential unique functional roles of ARAF. Other notable mu-
tant- and membrane-specific interactors include the mTORC2
complex described by Kovalski et al. and RSK1, of which we fo-
cused on the latter (47).
While RSK1 is known to be involved in the RAS pathway
downstream of ERK1/2 (60), RSK1 does not have an annotated
RBD. Additionally, RSK has been previously described to have
negative feedback effects on the RAS pathway via both inhibition
of SOS1 and activation of NF1 in the context of WT RAS (61, 65).
Although RSK1 and NF1 have been previously described to work
in parallel to feedback inhibit WT RAS, our findings reveal an
interaction between NF1 and RSK1. We demonstrate that the
RSK1 interaction with KRASG12D requires the expression of
NF1 and SPRED2, suggesting the existence of a protein complex
composed of mutant KRAS, NF1, RSK1, and SPRED2. Exper-
iments with the MEK inhibitor trametinib further show that the
proximity of RSK1 to KRASG12D depends on ERK signaling,
consistent with previous studies indicating that RSK1 activity is
downstream of ERK (60, 69). RSK1 has been previously shown to
transiently localize to the membrane upon EGF stimulation, and
its interaction with NF1 and KRAS may mechanistically explain
this observation (59). We show that membrane targeting of RSK1
does not impair the proliferation of KRAS mutant PDAC cells.
However, pharmacological blockade or genetic ablation of mutant
KRAS sensitizes PDAC cells to growth suppression by membrane-
localized RSK1, consistent with RSK1 acting as a negative regu-
lator of WT RAS signaling.
We demonstrate that oncogenic KRAS engages NF1/RSK1 to
feedback inhibit WT RAS signaling. Consequently, the pharmaco-
logical targeting of oncogenic KRAS would disengage this negative
feedback pathway, activate WT RAS, and trigger adaptive re-
sistance. Indeed, we provide evidence that PDAC cells survive
the deletion of endogenous KRASG12V mutant in vitro; however,
concomitant blockade of WT RAS through SOS1 inhibition
completely impairs the fitness of these tumor cells. Additionally,
we show that blockade of WT RAS either by expressing mem-
brane RSK1 or pharmacologically through SOS1 inhibition en-
hances the efficacy of AMG 510, a selective KRASG12C inhibitor,
in KRASG12C-mutant tumor cells. Our work complements recent
studies that demonstrate synergy between KRASG12C inhibitors
and blockade of upstream activators of WT RAS, such as EGFR
or SHP2, and suggests that activation of WT RAS may play a
dominant role in the adaptive resistance to oncogenic KRAS-
directed therapies (68, 70).
While we demonstrate that membrane-localized RSK1 attenu-
ates WT RAS signaling, the importance of membrane-bound
RSK1 during tumor progression in KRAS mutant cells remains
to be determined. We show that one role for membrane-bound
RSK1 is to inhibit the signaling through WT RAS proteins during
mitogenesis. This may focus biochemical effectors on mutant RAS
oncoproteins to drive cancer. Alternatively, membrane-localized
RSK paralogs (particularly RSK1 and RSK2) have been shown to
promote invasion and metastasis of cancer cells (71). Indeed,
RSK1 with prolonged membrane localization may have a greater
opportunity to phosphorylate membrane-localized substrates that
promote cellular functions associated with tumorigenesis, includ-
ing increased cell proliferation, survival, migration, and glycolytic
flux (71–76). This would implicate a function for the NF1 tumor
suppressor protein in RAS-mutant cells. Consistent with such a
function is that biallelic mutations and complete suppression of
NF1 is rare in cancer (77). In conclusion, membrane-localized
RSK1 may promote cancer in several ways in vivo. This moti-
vates further study of the role of the NF1/RSK1 pathway in mu-
tant KRAS-driven PDAC.
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Constructs. The BirA R118G biotin-protein ligase gene including the multiple
cloning site was cloned from the pcDNA3.1 mycBioID plasmid deposited by
the Roux laboratory. Murine Kras was inserted between the multiple cloning
site of BirA R118G and SalI with GGCGGAAGCGGA, encoding for a short
glycine linker (GGSG). The C185S mutation was made with the Q5 Site-
Directed Mutagenesis Kit. BirA-CAAX control was created by fusing the
last 20 amino acids of murine KRAS4B to the C terminus of BirA. The
constructs were moved to pBABE-neo between BamHI and SalI for retroviral
production. For RSK1 overexpression, human RSK1 complementary DNA
(cDNA) was obtained from John Blenis via Addgene. The sequence (gggagt
agcaagagcaagcctaaggaccccagccagcgc) was added after the start codon of
the RSK1 cDNA to fuse a myr-tag to the N terminus. Both RSK1 and myr-
RSK1 were cloned into pBABE-neo between EcoRI and SalI. For gene editing,
lentiCas9-Blast (addgene no. 52962, deposited by the Feng Zhang labora-
tory) was used (78). Guides were designed using the Benchling CRISPR tool
against the first coding exon of each target gene with the best off-target
Fig. 5. Oncogenic KRAS engages an
RSK1/NF1 pathway to inhibit WT RAS in
pancreatic cancer cells. Schematics illus-
trating RSK1/NF1 interactions and known
mechanisms of RSK1-mediated negative
feedback on the RAS pathway. Mutant
KRAS activates the RAF/MEK/ERK/RSK and
PI3K/AKT pathways. Upon ERK activation,
RSK1 transiently localizes to the mem-
brane (59). (A) In KRAS-mutant PDAC cells,
RSK1 depends on MEK activity and NF1/
SPRED2 expression to be recruited to the
mutant-KRAS interactome on the mem-
brane. Membrane-localized RSK1 nega-
tively regulates RAS activation by inhibiting
the RasGEF, SOS1, and activating the
RasGAP, NF1. Compared to mutant RAS,
WT RAS exhibits greater sensitivity to RasGEFs
and RasGAPs; therefore, the RSK1-mediated
negative feedback mechanism potently
inhibits WT RAS but not mutant RAS. (B)
Upon mutant Kras ablation, decreased
SPRED2 expression and ERK-mediated
RSK1 phosphoactivation disengages the
negative feedback exerted on WT RAS by
NF1/RSK1, thereby enabling RAS-addicted
cells to survive.
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scores inserted into the ipUSEPR lentiviral vector (SI Appendix, Table S4).
Kinase-dead RSK plasmid was constructed by PCR-based cloning. Using
p-BABE-RSK plasmid as a template, the primer containing the mutations
(CATCTTGGTCCGGACGCGGTCACGTACTTTCAGCGTTGCCTTCTTCAGCACGCG-
CATAGCATACAGGTGCCCAC) and 5′ pBABE-RSK1 primer were used to amplify
the PCR products. The PCR products digested with EcoRI/BPEBI and MfeI/BSM
were subsequently subcloned into p-BABE-hRSK vector digested with
EcoRI/BPEBI and MfeI/BSMI, respectively. The mutations were confirmed by
Sanger sequencing.
Cell Culture. Phoenix, 293T, 3T3, mT42, mT93, mT95, and SUIT2 cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal
bovine serum (FBS) at 37 °C in 5% CO2 incubator. MIA PaCa-2 cells were
cultured in Roswell Park Memorial Institute Medium (RPMI 1640) with 10%
FBS. Cells for BioID experiments had their media changed to serum-free
DMEM with 50 μM biotin for 24 h prior to cell harvest.
Cell Lysis for Protein. Cells were washed five times with ice-cold phosphate-
buffered saline (PBS) prior to lysis with mild buffer (50 mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 0.7% Non-
idet P-40, 10% Glycerol, 1mM ethylenediaminetetraacetic acid (EDTA) with
Roche cOmplete Mini protease inhibitor tablet and Roche PhoSTOP phos-
phatase inhibitor. Lysates were spun at 16,900 × g for 10 min. The detergent-
compatible (DC) Protein Assay (Bio-Rad) was used to quantify the protein
concentration. For experiments using FPC cells, 2 μM of 4-hydroxytamoxifen
(4-OHT) with DMSO as the vehicle was added to the media for 3 d prior to
harvest. AMG 510 (Selleckchem, no. S8830) dissolved in DMSO was added to
RPMI for 24 h or as indicated in MIA PaCa-2 experiments. Buffers and pro-
tocol for sequential cell fractionation experiments were followed as laid out
in Baghirova et al. (53)
Pulldown and Immunoprecipitation. Cell lysates were harvested in mild
Nonidet P-40 buffer with protease and phosphatase inhibitor as described
above (50mM HEPES, 150 mM NaCl, 0.7% Nonidet P-40, 10% Glycerol, 1mM
EDTA) with Roche cOmplete Mini protease inhibitor tablet and Roche
PhoSTOP phosphatase inhibitor, at 0 °C. A total of 5 mg lysate in 1 mL total
buffer was incubated with 30 μl MyOne Streptavidin C1 Dynabeads or 5 mg
Myc-Tag (9B11) Mouse mAb (Cell Signaling, no. 2276) antibody for 3 h with
subsequent 1-h incubation with 30 μl Protein G Dynabeads for streptavidin
pulldown and myc-tag immunoprecipitation (IP), respectively. The beads
were washed five times in lysis buffer before elution in NuPAGE 3-(N-mor-
pholino)propanesulfonic acid (MOPS) sodium dodecyl sulfate (SDS) running
buffer at 95 °C.
MS Analysis. On-bead tryptic digestion of Dynabeads, liquid chromatography
with tandem mass spectrometry (LC-MS/MS), and database searching is
detailed in SI Appendix. Proteins quantified by only one peptide were
omitted from further analysis. All quantification of peptides was normalized
to that of BirA prior to producing relative enrichment by ratiometric anal-
ysis. The proteins were ranked by relative enrichment for each biological
replicate. The sum of the three assigned ranks was used to indicate a general
enrichment score for all three biological replicates to account for protein
expression differences across cell lines. The candidate interactors were then
sorted by their cumulative rank scores to identify consistently enriched
interactors. Candidate interactors met their respective criteria if they were
enriched in two of three biological replicates.
Cell Proliferation Assay.Mouse cell lines (3T3 cells and FPC cells) were plated at
1,000 cells per well while human cell lines (MIA PaCa-2, SUIT-2, and NCI-H358)
were plated at 2,000 cells per well. Five wells were used for technical rep-
licates. Pharmacological agents were added by HP D300 drug dispenser, and
cell viability was assayed daily using the CellTiter-Glo Assay and read on a
Spectramax i3 plate reader. For crystal violet staining, cells were plated in
6-well plates at a density of 5,000 cells per well and allowed to grow for 2 d
or 2,000 cells per well for 3 d. The cells were washed with ice-cold PBS twice
before methanol fixation for 20 min. These cells were then stained with a
crystal violet solution (0.5% crystal violet, 95% ethanol in water).
Statistical Analysis. Microsoft Excel and GraphPad Prism were used for
graphical representation of data. Statistical analysis was performed using
Student’s t test.
Data Availability.All study data are included in the article and/or SI Appendix.
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